Daily single-strength versus thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in solid organ transplant recipients: A randomized control trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220720010

Enrollment

200

Registered

2022-07-20

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult solid organ transplant recipients PCP kidney liver heart immunocompromised host

Interventions

Patients will be randomized 1:1 to receive Daily SS Bactrim after SOT,Patients will be randomized 1:1 to receive Thrice a week DS Bactrim after SOT

Active Comparator Drug,Experimental Drug

Daily SS Bactrim,Thrice a week DS Bactrim

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult SOT recipients

Exclusion criteria

Exclusion criteria: Unwilling to participate TMP/SMX allergy

Design outcomes

Primary

Measure	Time frame
Free from infection 6 months PCR	—

Secondary

Measure	Time frame
Safety 6 months Liver function test	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026